Biomarker ID | 1711 |
PMID | 26172920 |
Year | 2015 |
Biomarker | ERG |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in PCa (Tissue, Serum) |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.23 (95% CI: 1.01-1.49) |
Effect on Pathways | Pathway include: Chromatin Regulation / Acetylation; Endometrial cancer; Transcriptional misregulation in cancer; TarBasePathway |
Experiment | Recurrence Free Survival Vs No Recurrence Free Survival |
Type of Biomarker | Prognostic |
Cohort | 954 patients were chosen for the study out of which 435 experienced recurrenece free survival |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.04 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |